A massive new study of drug candidates sheds light on which experimental therapies are most likely to eventually reach the market. The report was compiled by biotech’s largest trade association, the Biotechnology Innovation Organization (BIO), with the help of business intelligence firms BioMedTracker and Amplion, and it found that drugs for blood disorders have the highest probability of ultimately winning FDA approval. Meanwhile, cancer drugs have the lowest chance of receiving the go-ahead. BIO&r
Crude oil and iron ore are two of the world’s most important industrial commodities, where supply and demand are tied to the fate of the global economy. Yet, they’re doing very different things right now. Oil in London traded above $50 a barrel for the first time since November, while iron is moving in the opposite direction and looks set to fall below $50 a ton any day. It’s a slightly artificial comparison -- there’s little physical equivalence between a barrel of oil and a ton of o
Biotechnology companies Celgene Corp. and Gilead Sciences Inc. are considering bids for Medivation Inc., which would pitch them against suitors led by French drugmaker Sanofi, according to people familiar with the matter. Celgene and Gilead are talking to advisers as they evaluate whether to pursue a bid for the cancer-therapy company, the people said, asking not to be identified because the deliberations are private. No formal sales process is under way yet and Celgene and Gilead could decide against m
China’s Yantai Xinchao Industry Co. is pursuing U.S. oil acquisitions worth as much as $1 billion in the Permian Basin, and it won’t be satisfied letting others run the show, according to the head of the company’s U.S. subsidiary. Unlike other Asian companies that bought stakes in U.S. energy prospects in recent years, Xinchao is seeking so-called operated positions, or deals that give it primary authority over everything from how deep to drill to how intensively to frack each well, said Cu
Tokyo-based Oncolys BioPharma has agreed to license China rights of its oncolytic virus candidate, OBP-301, to Jiangsu Hengrui Medicine for a therapy area that saw a first-in-class approval for Amgen's ($AMGN) Imlygic (talimogene laherparepvec) by the U.S. FDA last year. In a release, Oncolys said the board approved a binding letter-of-intent with Lianyungang-based Jiangsu Hengrui Medicine for the candidate known as telomelysin "to pave the way
The commodities market has turned a corner and prices are unlikely to return to lows seen in the first quarter, according to Citigroup Inc., which boosted forecasts from metals to grains amid an oil-led recovery. The bottom was likely hit earlier this year when weak fundamentals across all commodities were reinforced by selling after the collapse of China’s equity markets, Citigroup analysts including Ed Morse wrote in a report Tuesday. The bank is now predicting Brent oil will climb to $50 a barrel in
Canadian seafloor miner Nautilus Minerals (TSX, LON:NUS) posted Thursday upgraded mineral resource estimates for its underwater mining project in the Eastern Pacific, off the coast of Mex... Full Story
is pleased to announce that it has completed the construction of its new 300tpd Veta Dorada ore processing plant and has begun the commissioning process. The Veta Dorada plant... Full Story
Like MacDonald's all day breakfast we had an all day rally yesterday. Most traders when asked... Read More
The Dow and the S&P 500 have broken down below their 50 DMA. This is not good. We look mo... Read More
The FOMC minutes will be released at 2pm today. Traders were positioning in front of that by ... Read More
NAI500 is delighted to spend some time with the CEO of Cohbar Inc. (TSXV:COB.U), one of the emerg... Read More
The evidence is mounting: Resverlogix Corp.'s first-in-class, epigenetics-based drug cand... Read More
Volatility is the nature of the biotech beast, and it must be tamed or utilized to advantage. Tha... Read More
The year of 2015 completed with a flurry of deals and news that trigger our thoughts for what to look for in 2016. While the volatility of Chinese stock market still very much i... Read More
NAI500 comment: ——Obama has formally rejected the Keystone XL Pipeline proposal which would have built a 1,179 mile crude oil pipeline from Canada to US refineries. &mda... Read More
NAI500 Comments: i. The Chinese government is heavily focused on the health of its citizens as shown by its decision to build 7,500 public hospitals through the private sector over the... Read More
Gainey Capital Corp. is a well-funded, cash-flow positive gold and silver exploration company tha...
Rock Energy Inc is engaged in the exploration, development and production of crude oil and natura...
Imprimis Pharmaceuticals is a specialty pharmaceutical company focused on the development and com...